[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371596-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371596-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","beyond-transposons-tigd1-as-a-pan-cancer-biomarker-and-immune-modulator","Beyond Transposons - TIGD1 as a Pan-Cancer Biomarker and Immune Modulator","","TIGD1 (Trigger Transposable Element Derived 1) is a recently identified oncogene with largely uncharacterized biology. This study performs a comprehensive pan-cancer analysis to define its expression landscape, diagnostic performance, prognostic relevance, and links to immunotherapy response and drug resistance. Transcriptomic and clinical TCGA/GTEx data are integrated with bioinformatic analyses including survival, immune correlations, gene set enrichment, single-cell profiling, and drug-sensitivity assessment.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/beyond-transposons-tigd1-as-a-pan-cancer-biomarker-and-immune-modulator/371596/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/beyond-transposons-tigd1-as-a-pan-cancer-biomarker-and-immune-modulator/371596.png","ImageObject",300,407,{"name":42,"@type":43},"นรินทร์","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-15","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is TIGD1 and why was it studied across cancers?","Question",{"text":63,"@type":64},"TIGD1 is a recently identified oncogene whose biological functions are not well understood. Evidence suggests it may participate in multiple cancer-related cellular processes, motivating a pan-cancer evaluation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which data sources and methods were used to analyze TIGD1?",{"text":68,"@type":64},"The study analyzes transcriptomic and clinical data from TCGA and GTEx using bioinformatic tools. It includes expression profiling, survival analysis, immune correlation studies, gene set enrichment, single-cell sequencing, and drug sensitivity assessments.",{"name":70,"@type":61,"acceptedAnswer":71},"How does TIGD1 relate to prognosis and the tumor immune microenvironment?",{"text":72,"@type":64},"TIGD1 is upregulated in multiple tumor types and higher expression is associated with poor prognosis in several cancers. Its levels correlate with immune microenvironment features such as immune checkpoint gene expression, TMB, and MSI.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371596,1790245966,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":128,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","Article  \nBeyond Transposons: TIGD1 as a Pan-Cancer Biomarker and Immune Modulator  \nMerve Gulsen Bal Albayrak *, Tu ˘gcan Korak , Gurler Akpinar and Murat Kasap  \nAcademic Editors: Garrett M. Dancik and Spiros Vlahopoulos  \nReceived: 21 April 2025  \nRevised: 9 May 2025  \nAccepted: 13 May 2025  \nPublished: 30 May 2025  \nCitation: Bal Albayrak, M.G.; Korak, T.; Akpinar, G.; Kasap, M. Beyond Transposons: TIGD1 as a Pan-Cancer Biomarker and Immune Modulator. Genes 2025, 16, 674 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)genes16060674  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \nDepartment of Medical Biology, Faculty of Medicine, Kocaeli University, Kabaoglu District, Baki Komsuoglu Blvd.  \nNo:21, Umuttepe, 41001 Kocaeli, Turkey; [tugcan.korak@kocaeli.edu.tr](tugcan.korak@kocaeli.edu.tr) (T.K.); [gurlerak@kocaeli.edu.tr](gurlerak@kocaeli.edu.tr) (G.A.);  \n[mkasap@kocaeli.edu.tr](mkasap@kocaeli.edu.tr) (M.K.)  \n* [Correspondence: merve.bal@kocaeli.edu.tr](Correspondence: merve.bal@kocaeli.edu.tr); Tel.: +90-262-303-75-39  \nAbstract: Background/Objectives: TIGD1 (Trigger Transposable Element Derived 1) is a recently identified oncogene with largely unexplored biological functions. Emerging evidence suggests its involvement in multiple cellular processes across cancer types. This study aimed to perform a comprehensive pan-cancer analysis of TIGD1 to evaluate its expression patterns, diagnostic utility, prognostic value, and association with immunotherapy response and drug resistance. Methods: Transcriptomic and clinical data from TCGA and GTEx were analyzed using various bioinformatic tools. Expression profiling, survival analysis, immune correlation studies, gene set enrichment, single-cell sequencing, and drug sensitivity assessments were performed. Results: TIGD1 was found to be significantly upregulated in various tumor types, with notably high expression in colon adenocarcinoma. Elevated TIGD1 expression was associated with poor prognosis in several cancers. TIGD1 levels correlated with key features of the tumor immune microenvironment, including immune checkpoint gene expression, TMB, and MSI, suggesting a role in modulating antitumor immunity. GSEA and single-cell analyses implicated TIGD1 in oncogenic signaling pathways. Furthermore, high TIGD1 expression was linked to resistance to several therapeutic agents, including Zoledronate, Dasatinib, and BLU-667 . Conclusions: TIGD1 may serve as a promising diagnostic and prognostic biomarker, particularly in colon, gastric, liver, and lung cancers. Its strong associations with immune modulation and therapy resistance highlight its potential as a novel target for precision oncology and immunotherapeutic intervention.  \nKeywords: TIGD1; pan-cancer analysis; immune microenvironment; drug resistance; cancer prognosis; immunotherapy; tumor mutational burden; microsatellite instability  \n1. Introduction  \nCancer remains a major global health burden, necessitating the discovery of novel biomarkers for early detection, accurate prognosis, and effective treatment strategies [1,2]. Among the emerging areas of oncological research, transposable elements (TEs)—also known as mobile genetic elements—have garnered increasing attention due to their roles in genomic instability, epigenetic modulation, and immune regulation [3–6]. TEs constitute nearly half of the human genome and, although typically silenced by host epigenetic mechanisms, their aberrant reactivation in cancer can contribute to oncogenesis through insertional mutagenesis, dysregulated gene expression, and activation of immune evasion pathways [7].  \nIn addition to their genomic impact, TE-derived transc","cbCaihqAmlfKJIoR","https://ap.wps.com/l/cbCaihqAmlfKJIoR","pdf",25056096,"English","# Introduction\n## Background and rationale\n## Study aims\n# Abstract\n## Objectives\n## Methods\n## Results\n## Conclusions","[{\"question\":\"What is TIGD1 and why was it studied across cancers?\",\"answer\":\"TIGD1 is a recently identified oncogene whose biological functions are not well understood. Evidence suggests it may participate in multiple cancer-related cellular processes, motivating a pan-cancer evaluation.\"},{\"question\":\"Which data sources and methods were used to analyze TIGD1?\",\"answer\":\"The study analyzes transcriptomic and clinical data from TCGA and GTEx using bioinformatic tools. It includes expression profiling, survival analysis, immune correlation studies, gene set enrichment, single-cell sequencing, and drug sensitivity assessments.\"},{\"question\":\"How does TIGD1 relate to prognosis and the tumor immune microenvironment?\",\"answer\":\"TIGD1 is upregulated in multiple tumor types and higher expression is associated with poor prognosis in several cancers. Its levels correlate with immune microenvironment features such as immune checkpoint gene expression, TMB, and MSI.\"}]","Beyond Transposons - TIGD1 as a Pan-Cancer Biomarker and Immune Modulator | PDF",1790192413,48,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69a9ca7aca41f7dfc625d91e53452b36.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87567af58fc2f39af159e2f02fefa80f.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12d560be578a366731f8dac896184210.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d62605c8806ffcc746a1d0492cab8ab.webp",980,1385]